By HospiMedica International staff writers
Posted on 30 Sep 2020
The outbreak of respiratory infection based pandemic diseases like COVID-19 is fueling global demand for face masks among frontline health workers such as first responders, nurses, and medical practitioners. Most commercially available masks are unable to efficiently filter the tiny aerosols that contain the virus. Viruses that are attached to the filtering materials can penetrate through a moist mask and, thus, increase the risk of infection.
AXIM Biotechnologies, Inc. (San Diego, CA, USA) has filed a provisional patent for a first-in-class face mask that captures and deactivates SARS-CoV-2. AXIM’s novel face mask is designed to provide enhanced protection from infection by capturing the viruses in the face mask filter layer before it reaches or after it exits the user’s respiratory system. To accomplish the goal of capturing SARS-CoV-2 on the face mask, AXIM has developed a cost-effective treatment for the face mask surfaces that utilizes a proprietary set of reagents that are permanently embedded into the mask filter which then captures the virus instantaneously on contact.